Daily Oncology News

The ESMO OncologyPRO news, provided in partnership with medwireNews, ensures that you're always kept up to date with the latest developments in the field of medical oncology. You can browse articles by date or by topic.

Browse archives for older articles from 2018 , 2017 , 2016 (all articles may be found in search)
These articles are Open Access.

Did you know how medwireNews writes our articles?

Filter

Date Title Topic
21 Oct 2019 Post-Treatment ctDNA Linked To Stage III Colon Cancer Prognosis Colon and Rectal Cancer - Translational Research
18 Oct 2019 Tumour Treating Fields Therapy Shows ‘Promising’ OS For Unresectable Mesothelioma Mesothelioma - Clinical Research - Anticancer Agents
17 Oct 2019 Early Findings Point To First-Line Metastatic CRC Response To Panitumumab Plus FOLFOXIRI Colon and Rectal Cancer - Anticancer Agents
16 Oct 2019 PACIFIC PROs Indicate Durvalumab Does Not Reduce NSCLC QoL Non-Small Cell Lung Cancer - Immunotherapy
15 Oct 2019 Veliparib Combination Plus Maintenance Extends PFS For Advanced Serous Ovarian Carcinoma Ovarian Cancer - Personalised/Precision Medicine - Anticancer Agents
14 Oct 2019 Targeted Agent May Improve Survival For IDH1-Mutated Advanced Cholangiocarcinoma Hepatobiliary Cancers - Personalised/Precision Medicine - Anticancer Agents
11 Oct 2019 CASPIAN PROs Support Durvalumab Use For Extensive-Stage SCLC Small Cell Lung Cancer - Anticancer Agents - Immunotherapy
10 Oct 2019 BEACON CRC Triple Regimen Boosts BRAF V600E-Mutated Metastatic CRC Survival Colon and Rectal Cancer - Personalised/Precision Medicine - Anticancer Agents
09 Oct 2019 ATTRACTION-3 Confirms Nivolumab OS Benefit For Advanced Oesphageal Carcinoma Oesophageal Cancer - Anticancer Agents - Immunotherapy
08 Oct 2019 Cabazitaxel Benefit Demonstrated For metastatic CRPC Patients Prostate Cancer - Anticancer Agents
07 Oct 2019 PAOLA-1 Supports Olaparib–Bevacizumab Maintenance For HRD-Positive Advanced Ovarian Cancer Ovarian Cancer - Personalised/Precision Medicine - Anticancer Agents
04 Oct 2019 Niraparib Results Suggest First-Line Maintenance PARP Inhibitor For Advanced Ovarian Cancer Ovarian Cancer - Personalised/Precision Medicine - Anticancer Agents
03 Oct 2019 Olaparib May Have PROfound Effect On mCRPC Prostate Cancer - Personalised/Precision Medicine - Anticancer Agents
02 Oct 2019 FLAURA: First-Line OS Benefit Confirmed For Advanced EGFR-Mutated NSCLC Non-Small Cell Lung Cancer - Personalised/Precision Medicine - Anticancer Agents
01 Oct 2019 Pembrolizumab Shows Early Triple-Negative Breast Cancer Potential Breast Cancer - Anticancer Agents - Immunotherapy